JZP-150

JZP-150 is a highly selective small molecule inhibitor of the enzyme fatty acid amide hydrolase (FAAH). FAAH is responsible for the degradation of endocannabinoids such as anandamide. By inhibiting FAAH, JZP-150 increases levels of these endogenous cannabinoids in the brain. The drug was developed to address conditions where modulation of endocannabinoid signaling may be beneficial, particularly post-traumatic stress disorder (PTSD), by potentially improving fear extinction learning and reducing anxiety-related symptoms. Originally discovered by Pfizer and previously known as PF-04457845, development was later led by Jazz Pharmaceuticals. Despite promising preclinical data and Fast Track designation from the FDA for PTSD, clinical trials failed to demonstrate efficacy over placebo in Phase 2 studies for PTSD. Development has been discontinued for PTSD and other indications including pain and alcoholism[1][4][5][9].

Other names

redafamdastat